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 ABSTRACT 
 
OBJECTIVE:  The objective of this systematic review is to determine whether or not 
narrowband ultraviolet B (NB-UVB) phototherapy is effective monotherapy in the treatment of 
adults with plaque psoriasis. 
 
STUDY DESIGN: Review of three English language primary randomized controlled studies 
published in 2006 and 2009. 
 
DATA SOURCES: Randomized, investigator-blind, active treatment-controlled trials comparing 
NB-UVB phototherapy to other treatment options were found using MEDLINE, OVID, and 
COCHRANE databases. 
 
OUTCOME(S) MEASURED: Each of the three trials assessed improvement of the overall 
psoriatic lesions by the investigator and the patient based on the presence and severity of 
erythema, scaling, induration, itch, redness/irritation, burning sensation, height of lesion, 
size/area, and roughness/texture. Investigators completed a Psoriasis Area Severity Index score, 
Physician’s Global Assessment of Clearance, and rated severity of symptoms on a scale of 0 
(none) to 4 (severe).  Patients completed a Dermatology Quality of Life Index, Visual Analog 
Scale from 0 (none) to 10 (worse ever experienced), and rated severity of symptoms on a scale of 
0 (none) to 6 (severe). 
 
RESULTS: Three randomized controlled trials were included in this review.  Results from each 
trial indicate that NB-UVB monotherapy can successfully treat plaque psoriasis in that it 
provides relief of symptoms and clearance of the lesions.  However, although NB-UVB was 
effective, each of the comparison treatments demonstrated alleviation of symptoms and treatment 
of lesions in a shorter period of time.  In all three trials, erythema was found to be an adverse 
reaction. 
 
CONCLUSIONS: Each trial portrays that NB-UVB is effective monotherapy for the treatment of 
plaque psoriasis.  In spite of this, the efficiency of this treatment option is of question due to the 
findings that the comparison treatment options showed a more prompt clearance of lesions. 
 
KEY WORDS: Psoriasis; UVB; phototherapy
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INTRODUCTION  
 Psoriasis is a genetically inherited dermatologic condition that affects 1.5 to 2% of 
the world’s western population, and it currently affects 7.5 million people in the United States.1,2 
This diagnosis has multiple different presentations such as plaque psoriasis, guttate psoriasis, 
pustular psoriasis, inverse psoriasis, amongst others.  Eighty to ninety percent of psoriasis 
patients have plaque-type psoriasis.
1
  Plaque psoriasis specifically can cause physical and 
cosmetic problems for patients, which can in turn lead to a negative impact on the patient’s 
quality of life.  These patients typically present with erythematous raised patches of silvery skin 
which are mainly found on the extensor surfaces of the body, and can lead to long term sequelae.  
 Unfortunately, at the current time, there is no cure for psoriasis.  It is estimated that 
$11.25 billion are spent annually for psoriasis patients, and it has been reported that more than 
three million health care visits occur each year.
2,3
  The exact cause of psoriasis is unknown; 
however, at this time it has been found that there is an autoimmune component which involves 
an overstimulated T-cell response of the immune system, as well as increased cell turn over time 
of the keratinocytes.
1
  Physician assistants working in primary care settings may be the first 
healthcare provider to recognize and educate patients on the diagnosis of plaque-type psoriasis.  
Gaining knowledge and being able to prescribe a patient with the best treatment options is an 
important role for physician assistants as the condition can be uncomfortable both physically and 
cosmetically for the patient. 
 There are multiple treatment options available for the condition.  Common systemic 
methods include narrowband ultraviolet B (NB-UVB) phototherapy, oral psoralen-ultraviolet-A 
(PUVA) photochemotherapy such as 8-methoxypsoralen (8-MOP) and exposure to UVA, oral 
retinoids such as aceitretin and isotretoin, oral methotrexate, oral cyclosporin, and monoclonal 
Cardine: UVB Phototherapy and Psoriasis 
 
2 
antibodies such as alefacept, efalizumab, infliximab, adalimmab, and etanercept.
1
  Adjunctive 
therapy is also available for localized plaques including topical glucocorticoids, vitamin D 
analogues, tararotene, and topical tacrolimus/pimecrolimus.
1
  The treatment options mentioned 
above all play an effective role in treating psoriasis.  However, as with all medications, each 
option will have a different effect on each patient with different rates of efficacy and adverse 
reactions.  NB-UVB phototherapy has been shown to be effective in the treatment of generalized 
plaque psoriasis, and will be discussed further in this review. 
OBJECTIVE 
 The objective of this systematic review is to determine whether or not NB-UVB 
phototherapy is effective monotherapy in the treatment of adults with plaque psoriasis. 
METHODS 
 Each of the three studies selected were randomized controlled clinical trials and met the 
following criteria.  The population included patients who were greater than 18 years of age with 
diagnosed chronic, stable, plaque psoriasis.  The intervention used consisted of NB-UVB 
phototherapy.  This intervention was compared to a different treatment option in each of the 
three different studies.  These comparisons included 0.1% 8-MOP cream followed within 15 
minutes by NB-UVB phototherapy, 15% liquor carbonis distillate (LCD) solution plus NB-UVB 
phototherapy, and a 10 mg 8-MOP tablet two hours before receiving PUVA.  Outcomes of each 
of the treatment options were determined by the improvement of the overall psoriatic lesions 
which were assessed by the investigator and the patient.  These improvements were based on the 
presence and severity of erythema, scaling, induration, itch, redness/irritation, burning sensation, 
height of lesion, size/area, and roughness/texture.   
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Key words used to locate literature were psoriasis, UVB, and phototherapy.  All articles 
were published in English, and published in peer- reviewed journals.  Research for the articles 
was performed by the author via MEDLINE, OVID, and COCHRANE databases.  Articles were 
selected based on relevance and that the outcomes of the studies mattered to patients (POEMs).  
Inclusion criteria for consideration of the study was that it was a randomized controlled trial 
published after 1996.  Exclusion criteria included patients who were under the age of 18 years 
old, had recent treatment for psoriasis, or photosensitivity disorders.  Statistics were reported 
using p-value, numbers needed to treat (NNT), relative benefit increase (RBI), and absolute 
benefit increase (ABI). 
OUTCOMES MEASURED 
 Each of the three trials assessed improvement of the overall psoriatic lesions.  This 
assessment was completed by both the investigator and the patient based on the presence and 
severity of erythema, scaling, induration, itch, redness/irritation, burning sensation, height of 
lesion, size/area, and roughness/texture of the lesions. Investigators completed a Psoriasis Area 
Severity Index (PSI-95) score, the Physician’s Global Assessment of Clearance, and rated the 
severity of symptoms on a scale of 0 (none) to 4 (severe).  Patients completed a Dermatology 
Quality of Life Index, Visual Analog Scale from 0 (none) to 10 (worse ever experienced), and 
rated severity of symptoms on a scale of 0 (none) to 6 (severe).  Digital photographs were also 
taken throughout the studies to demonstrate the improvement of the lesions.  
Bagel also asked patients to evaluate the comparison treatment option which was LCD.  
Patients graded the product on a scale of 1 (poor) to 9 (excellent).  Each parameter used to 
determine the outcome of each study was patient-oriented evidence that matters to the patient 
involved. 
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Table 1. Demographics and characteristics of included studies. 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Amor-
npiny-
okeit, 
2006 (1) 
RCT 12 18-61 Patients who 
were 18 years or 
older with 
stable, plaque-
type psoriasis 
Patients who received 
photo (chemo) 
therapy within the 
past 8 wks, topical 
treatments within the 
past 4 wks, are 
pregnant, lactating, 
have a  
hypersensitivity to 
psoralen, or have 
photosensitivity 
disorders 
2 NB-UVB 
phototherapy VS. 
0.1% 8-MOP 
cream, followed 
within 15 minutes 
by NB-UVB 
phototherapy 
Bagel, 
2009 (2) 
RCT  13 25-67 Adults who 
were in good 
health apart 
from the 
diagnosis of 
chronic 
symmetrically 
distributed 
plaque psoriasis 
 
Patients who were 
receiving any other 
treatments for 
psoriasis, or who had 
intolerance to coal tar 
or ultraviolet 
radiation. 
1 NB-UVB 
phototherapy VS. 
100 mL of 15% 
liquor carbonis 
distillate (LCD) 
solution applied 
BID to psoriatic 
lesions (except 
face,scalp,groin) 
plus NB-UVB 
phototherapy 
Yones, 
2006 (3) 
RCT  93 18-70 Patients 18-70 
years old with 
chronic plaque 
psoriasis with at 
least 8% body 
surface area 
involvement 
with a Psoriasis 
Area and 
Severity Index 
(PASI) score of 
at least 8 
 
Patients with 
previous skin 
malignancy, recent 
photo(chemo)therapy 
or > 150 sessions in 
lifetime, history of or 
use of a drug causing 
photosensitivity, 
topical/systemic 
antipsoriatic 
treatment in the past 
3 months pregnancy, 
lactation, or 
renal/hepatic disease 
5 Placebo tablet 2 
hours before 
receiving NB-UVB 
phototherapy VS. 
10 mg 8-
methoxypsoralen 
tablet 2 hours 
before receiving 
psoralen-
ultraviolet-A 
(PUVA)  
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RESULTS 
 The results of each of the three trials evaluated were presented as dichotomous data in 
order to evaluate the improvement of the lesions with NB-UVB monotherapy.   
 Amornpinyokeit et al found that of the ten patients involved in the study, three patients 
achieved clearance of the psoriatic lesions with NB-UVB monotherapy.  However, four of the 
ten patients experienced clearance with 8-MOP/NB-UVB combination therapy.  This data 
demonstrates that there is a -25% RBI and a -10% ABI when comparing NB-UVB with             
8-MOP/UVB combination therapy.  NNT for this study was found to be -10 patients and the      
p-value was 0.199 (Table 2).  The negative value of NNT indicates that for every ten patients 
who were given NB-UVB monotherapy, there would be one fewer patient who would achieve 
PSI-95 than if they would have been treated with the combination therapy. 
 Yones et al compared the treatment of NB-UVB and 8-MOP/PUVA combination in a 
study enrolled with eighty-eight patients.  It was calculated that the RBI was -35% and the ABI 
was -28%.  The NNT was determined to the -4 patients and neither a p-value nor confidence 
interval was given (Table 2).  The negative value of NNT in this study indicates that for every 
four patients who were given UVB monotherapy, there would be one fewer patient who would 
have complete clearance than if they would have been treated with the combination                     
8-MOP/PUVA. 
 The study performed by Bagel determined the results of NB-UVB monotherapy versus 
LCD/NB-UVB combination therapy.  RBI and ABI were calculated to be -14.2% and -8.3%, 
respectively.  NNT was -13 patients and p-value was reported to be insignificant (Table 2).  In 
this trial, the negative value of NNT indicates that for every thirteen patients who were given 
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UVB monotherapy, there would be one fewer patient who would have complete clearance than if 
they would have been treated with the combination LCD/UVB therapy. 
Table 2. Analysis of efficacy and safety in the evaluation of the clearance of psoriatic 
lesions with NB-UVB monotherapy. 
Study Relative 
benefit 
increase (RBI) 
Absolute 
benefit increase 
(ABI) 
Number needed 
to treat (NNT) 
p-value 
Amornpinyokeit, 
2006 
-25% -10% -10 0.199 
Yones, 2006 -35% -28% -4 Not given 
Bagel, 2009 -14.2% -8.3% -13 Insignificant 
 
  In addition to the overall evaluation of the clearance of the lesions, each of the clinical 
trials determined the mean number of treatment sessions the patients underwent in order to 
obtain PSI-95.  Each of the three studies showed to have a reduced amount of sessions needed 
for clearance when using the comparison treatment option.  As can be seen in Table 3, patients 
who received the 8-MOP/UVB treatment, the 8-MOP/PUVA combination therapy, or the 
LCD/NB-UVB treatment achieved clearance in an average of 5 sessions, 11.5 sessions, and  9 
sessions, respectively, less than when treated with NB-UVB monotherapy.  Therefore, although 
both lesions receiving treatment cleared with time regardless of the treatment option used, results 
showed that “the side that received the combination cleared faster than the contralateral lesions 
receiving the NB-UVB treatment...however, did not find that such combinations were superior to 
NB-UVB alone.” 4  
 Furthermore, two of the three trials discussed the length of time until the patient 
experienced relapse of their psoriatic lesions.  This data is also presented in Table 3 and 
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reinforces the lack of cure for plaque type psoriasis, as all patients relapsed with time regardless 
of treatment.  In the trial conducted by Amornpinyokeit et al, all patients had relapse of lesions 
by twelve weeks with both the NB-UVB monotherapy and 8-MOP/NB-UVB combination 
therapy.  Similar results were found with the comparison of the NB-UVB monotherapy versus 
the  8-MOP/PUVA combination.  Yones et al reported “that patients treated with PUVA had 
significantly longer remissions, with the median time to relapse being eight months versus four 
months among patients being treated with NB-UVB.” 5 
Table 3. Number of treatment session until clearance of lesions and length of time until 
remission.  
Treatment Number of treatment 
sessions until clearance  
Length of time  
until remission 
NB-UVB monotherapy 
vs. 8-MOP/NB-UVB 
7.67 vs. 2.50 All patients relapsed by 12 
weeks post-treatment 
NB-UVB monotherapy  
vs. 8-MOP/PUVA 
28.5 vs 17.0 16 weeks vs. 32 weeks  
NB-UVB monotherapy 
vs. LCD/NB-UVB 
21.0 vs 12.0 Not discussed 
 
 Lastly, adverse effects of the treatment options were discussed in each of the trials.  
Among the three studies, no major complications were encountered.  The most common 
complication reported was erythema which was reported in each trial to a different degree.  The 
information is displayed below in Table 4.  All ten patients enrolled in the Amornpinyokeit et al 
study reported erythema with both treatment options.  In the trial conducted by Yones et al, a 
significantly less amount of erythema was reported by those who underwent the NB-UVB 
therapy versus the 8-MOP/PUVA combination therapy with reported cases being 22% versus 
49% respectively.  The study that evaluated LCD/NB-UVB therapy was more specific in 
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documenting the degree of erythema.  Bagel stated that “adverse reactions consisted of one 
report of mild and two reports of moderate post-UVB erythema, which appeared uniformly on 
both sides of the body.” 6 
Table 4.  Adverse Effects: Erythema reported during trials 
Treatment Reported cases of erythema Percentage 
NB-UVB monotherapy 
vs. 8-MOP/NB-UVB 
10/10 vs. 10/10  
of enrolled patients 
100% vs. 100% 
NB-UVB monotherapy  
vs. 8-MOP/PUVA 
10/45 vs. 21/43  
of enrolled patients 
22% vs 49% 
NB-UVB monotherapy 
vs. LCD/NB-UVB 
3/12 vs 3/12  
of enrolled patients 
25% vs 25% 
 
DISCUSSION 
 NB-UVB has been shown to be an effective treatment option for plaque-type psoriasis, as 
demonstrated through each of the trails discussed above.  This type of phototherapy is also 
utilized to treat many other dermatological diagnoses.  NB-UVB treatment is a readily accepted 
and available treatment option in the United States.  Despite this, healthcare professionals may 
encounter problems with patient compliance due to the frequent and continuous need for 
phototherapy sessions, as well as its cost.  Common side effects encountered while using NB-
UVB are erythema, hyperpigmentation, photosensitivity, and worsening of the condition.  
Erythema is the most prevalent adverse reaction,  and was reported to some extent in each of the 
clinical trials.  This side effect may be avoided by beginning the treatment at a lower dosage.  
Contraindications for the use of NB-UVB are photosensitivity disorders, chronic phototherapy 
use in the past, pregnancy, lactation, and previous or current skin cancer. 
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 Although the data presented supports the use of NB-UVB, not all of the data presented in 
this review is considered to be clinically significant as shown by the p-values in the studies by 
Amornpinyokeit et al and Bagel et al.   Also, study size in these trials puts a limit on the validity 
of the results, with participants only adding up to a total of 110 patients for all three trials.  
CONCLUSION 
 In conclusion, NB-UVB phototherapy is an effective monotherapy for the treatment of 
adults with plaque psoriasis.  However,  other treatment options have been presented and have 
also been shown be effective for clearance of lesions and alleviation of symptoms for psoriasis 
patients.  Therefore, an important conclusion can be made that NB-UVB phototherapy alone may 
be a less efficient treatment option, but it is not a less superior treatment when compared to other 
options available.   
 Future research for the use of NB-UVB phototherapy would be beneficial if the trial was 
exclusively for patients with the same skin types in order to focus on the most effective dosage to 
achieve resolution without sustaining adverse effects.  Also, the future for the treatment of adults 
with plaque-type psoriasis includes finding a cure; therefore, research that would lengthen 
remission time and ultimately eliminate remission all together would provide the most benefit. 
 
 REFERENCES 
1
 Wolff K, Johnson RA. Fitzpatrick’s Color Atlas & Synopsis of Clinical Dermatology. 6th ed. 
New York, NY: The McGraw-Hill Companies; 2009: 53-71. 
 
2
 About psoriasis: Statistics. National Psoriasis Foundation Website. 
http://www.psoriasis.org/netcommunity/learn/about-psoriasis/statistics. Accessed October 2, 
2010. 
 
3
 Marchetti A, Feldman SR, Kimball AB, et al. Treatment for mild-to-moderate recalcitrant 
plaque psoriasis: Expected clincal and economic outcomes for first-line and second line care. 
Dermatology Online Journal. 2005; 11 (1): 1. 
http://dermatology.cdlib.org/111/original/psoriasis/marchetti2.html. Accessed October 2, 2010. 
 
4
 Amornpinyokeit N, Asawanonda P.  8-methoxypsoralen cream plus targeted narrowband 
ultraviolet B for psoriasis.  Photodermatol Photoimmunol Photomed. 2006; 22: 285-289. 
 
5
 Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the 
treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B 
therapy. Arch Dermatol. 2006; 142: 836-842. 
 
6 
Bagel J.  LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone.  J 
Drug Dermatol. 2009; 8 (4): 351-357. 
 
 
